KR970701564A - 맥관형성 억제에 유용한 방법 및 조성물(Methods and compositions useful for inhibition of angiogenesis) - Google Patents
맥관형성 억제에 유용한 방법 및 조성물(Methods and compositions useful for inhibition of angiogenesis) Download PDFInfo
- Publication number
- KR970701564A KR970701564A KR1019960705163A KR19960705163A KR970701564A KR 970701564 A KR970701564 A KR 970701564A KR 1019960705163 A KR1019960705163 A KR 1019960705163A KR 19960705163 A KR19960705163 A KR 19960705163A KR 970701564 A KR970701564 A KR 970701564A
- Authority
- KR
- South Korea
- Prior art keywords
- tissue
- angiogenesis
- administration
- antagonist
- seq
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 52
- 239000000203 mixture Substances 0.000 title claims 4
- 230000014399 negative regulation of angiogenesis Effects 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 claims abstract 21
- 239000005557 antagonist Substances 0.000 claims abstract 4
- HGFOOLONGOBCMP-IBGZPJMESA-N (3s)-3-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=NC(OC)=CC=C1[C@H](CC(O)=O)N1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 HGFOOLONGOBCMP-IBGZPJMESA-N 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102000008946 Fibrinogen Human genes 0.000 claims 6
- 108010049003 Fibrinogen Proteins 0.000 claims 6
- 206010003246 arthritis Diseases 0.000 claims 6
- 229940012952 fibrinogen Drugs 0.000 claims 6
- 230000002757 inflammatory effect Effects 0.000 claims 6
- 238000001990 intravenous administration Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 206010038910 Retinitis Diseases 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000011066 hemangioma Diseases 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 230000004263 retinal angiogenesis Effects 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 230000005747 tumor angiogenesis Effects 0.000 claims 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 101500027988 Mus musculus ADGRV1 subunit beta Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
Abstract
본 발명은 비트로넥티 αvβ3길항제를 사용하여 조직내에서 맥관형성을 억제하는 방법, 특히 염증 조직, 종양 조직 및 전이조직에서 αvβ3길항제를 함유하는 치료학적 조성물을 사용하여 맥관형성을 억제하는 방법을 서술한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (54)
- 맥관형성 억제량의 αvβ3길항제를 포함하는 조성물을 조직에 투여하는 것을 포함하는 상기 조직내에서 맥관형성을 억제하는 방법.
- 제1항에 있어서, αvβ3길항제가 αvβ3에 대한 피브리노겐의 결합을 억제하나 실질적으로 αIIbβ3 또는αvβ1에 대한 피브리노겐의 결합은 억제하지 않는 방법.
- 제1항에 있어서, αvβ3길항제가 αvβ3에 대한 면역특이적인 모노클로날 항체인 방법.
- 제3항에 있어서, 모노클로날 항체가 모노클로날 항체 LM609(ATCC HB 9537)의 면역 반응 특성을 가지는 방법.
- 제1항에 있어서, αvβ3길항제가 RGD-함유 폴리펩타이드인 방법.
- 제5항에 있어서, 폴리펩타이드가 c-(GrGDFV)(서열확인번호 4), c-(RGDfV)(서열확인번호 5), c-(RGDFv)(서열확인번호 7) 및 YTAECKPQVTRGDVF(서열확인번호 8) 및 이의 염으로 이루어지는 그룹중에서 선택되는 방법.
- 제6항에 잇어서, 염의 하이드로클로라이드 또는 트리플루오로아세테이트인 방법.
- 제1항에 있어서, 조직이 염증조직이고 맥관형성이 염증조직의 맥관형성인 방법.
- 제8항에 있어서, 조직이 관절염 조직인 방법.
- 제9항에 있어서, 관절염 조직이 류마티스성 관절염을 가진 포유동물내에 존재하는 방법.
- 제1항에 있어서, 조직이 당뇨병성 망막염 환자의 망막 조직이고 맥관형성이 망막 맥관형성인 방법.
- 제1항에 있어서, 조직이 혈관종인 방법.
- 제1항에 있어서, 조직이 고형 종양 또는 고형 종양 전이조직이고 맥관형성이 종양 맥관형성인 방법.
- 제1항에 있어서, 맥관형성 억제량이 약 2μM 내지 50mM인 방법.
- 제1항에 있어서, 투여가 정맥내 투여, 경피 투여, 활막내 투여, 근육내 투여 또는 경구 투여를 포함하는 방법.
- 제1항에 있어서, 투여가 화학치료법과 함께 수행되는 방법.
- 제1항에 있어서, 투여가 단일 용량의 정맥내 투여를 포함하는 방법.
- 맥관형성 억제량의 αvβ3길항제를 포함하는 조성물을 조직내로 투여하는 것을 포함하는, 조직내에서 구축된 종양을 퇴행시키는 방법.
- 제18항에 있어서, αvβ3길항제가 αvβ3에 대한 피브리노겐의 결합을 억제하나 실질적으로 αvβ3또는 αvβ3에 대한 피브리노겐의 결합은 억제하지 않는 방법.
- 제18항에 있어서, αvβ3길항제가 αvβ3에 대한 면역특이적인 모노클로날 항체인 방법.
- 제20항에 있어서, 모노클로날 항체가 모노클로날 항체 LM609(ATCC HB 9537)의 면역 반응 특성을 가지는 방법.
- 제18항에 있어서, αvβ3길항제가 RGD-함유 폴리펩타이드인 방법.
- 제22항에 있어서, 폴리펩타이드가 c-(GrGDFV)(서열확인번호 4), c-(RGDfV)(서열확인번호 5), c-(RGDFv)(서열확인번호 7) 및 YTAECKPQVTRGDVF(서열확인번호 8) 및 이의 염으로 이루어지는 그룹중에서 선택되는 방법.
- 제23항에 있어서, 염의 하이드로클로라이드 또는 트리플루오로아세테이트인 방법.
- 제18항에 있어서, 조직이 염증 조직이고 맥관형성이 염증 조직의 맥관형성인 방법.
- 제25항에 있어서, 조직이 관절염 조직인 방법.
- 제26항에 있어서, 관절염 조직이 류마티스성 관절염을 가진 포유동물내에 존재하는 방법.
- 제18항에 있어서, 조직이 당뇨병성 망막염 환자의 망막 조직이고 맥관형성이 망막 맥관형성인 방법.
- 제18항에 있어서, 조직이 혈관종인 방법.
- 제18항에 있어서, 조직이 고형 종양 또는 고형 종양 전이조직이고 맥관형성이 종양 맥관형성인 방법.
- 제18항에 있어서, 맥관형성 억제량이 약 2μM 내지 5mM인 방법.
- 제18항에 있어서, 투여가 정맥내 투여, 경피 투여, 활막내 투여, 근육내 투여 또는 경구 투여를 포함하는 방법.
- 제18항에 있어서, 투여가 화학치료법과 함께 수행되는 방법.
- 제18항에 있어서, 투여가 단일 용량의 정맥내 투여를 포함하는 방법.
- 제18항에 있어서, 퇴화가 맥관형성 억제 길항제를 투여한지 7일 후에 일어나는 방법.
- 맥관형성 억제량의 αvβ3길항제를 포함하는 조성물을 조직내로 투여하는 것을 포함하는 조직내 혈관신생에서 세포사멸(apoptosis)을 유도하는 방법.
- 제36항에 있어서, αvβ3길항제가 αvβ3에 대한 피브리노겐의 결합을 억제하나 실질적으로 αIIbβ3또는 αvβ1에 대한 피브리노겐의 결합은 억제하지 않는 방법.
- 제36항에 있어서, αvβ3길항제가 αvβ3에 대한 면역특이적인 모노클로날 항체인 방법.
- 제38항에 있어서, 모노클로날 항체가 모노클로날 항체 LM609(ATCC HB 9537)의 면역 반응 특성을 가지는 방법.
- 제36항에 있어서, αvβ3길항제가 RGD-함유 폴리펩타이드인 방법.
- 제40항에 있어서, 폴리펩타이드가 c-(GrGDFV)(서열확인번호 4), c-(RGDfV)(서열확인번호 5), c-(RGDFv)(서열확인번호 7) 및 YTAECKPQVTRGDVF(서열확인번호 8) 및 이의 염으로 이루어지는 그룹중에서 선택되는 방법.
- 제41항에 있어서, 염의 하이드로클로라이드 또는 트리플루오로아세테이트인 방법.
- 제36항에 있어서, 조직이 염증 조직이고 맥관형성이 염증 조직의 맥관형성인 방법.
- 제43항에 있어서, 조직이 관절염 조직인 방법.
- 제44항에 있어서, 관절염 조직이 류마티스성 관절염을 가진 포유동물내에 존재하는 방법.
- 제36항에 있어서, 조직이 당뇨병성 망막염 환자의 망막 조직이고 맥관형성이 망막 맥관형성인 방법.
- 제36항에 있어서, 조직이 혈관종인 방법.
- 제36항에 있어서, 조직이 고형 종양 도는 고형 종양 전이조직이고 백관형성이 종양 맥관형성인 방법.
- 제36항에 있어서, 맥관형성 억제량이 약 2μM 내지 5mM인 방법.
- 제36항에 있어서, 투여가 정맥내 투여, 경피 투여, 활막내 투여, 근육내 투여 또는 경구 투여를 포함하는 방법.
- 제36항에 있어서, 투여가 화학치료법과 함께 수행되는 방법.
- 제36항에 있어서, 투여가 단일 용량의 정맥내 투여를 포함하는 방법.
- 제36항에 있어서, 세포사멸이 맥관형성 억제 길항제를 투여한지 48시간 이후에 일어나는 방법.
- 제1항에 있어서, 조직이 관상동맥 혈관성형술이후 재발협착증의 위험이 있는 관상동맥인 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/210,715 US5753230A (en) | 1994-03-18 | 1994-03-18 | Methods and compositions useful for inhibition of angiogenesis |
US08/210,715 | 1994-03-18 | ||
US08/366,665 | 1994-12-30 | ||
US08/366,665 US5766591A (en) | 1994-03-18 | 1994-12-30 | Methods and compositions useful for inhibition of angiogenesis |
PCT/US1995/003035 WO1995025543A1 (en) | 1994-03-18 | 1995-03-09 | Methods and compositions useful for inhibition of angiogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970701564A true KR970701564A (ko) | 1997-04-12 |
KR100327081B1 KR100327081B1 (ko) | 2002-10-18 |
Family
ID=22783992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960705163A KR100327081B1 (ko) | 1994-03-18 | 1995-03-09 | 혈관형성억제에유용한조성물 |
Country Status (25)
Country | Link |
---|---|
US (7) | US5753230A (ko) |
EP (3) | EP1410807B1 (ko) |
JP (2) | JP4268222B2 (ko) |
KR (1) | KR100327081B1 (ko) |
CN (1) | CN1161152C (ko) |
AT (3) | ATE534403T1 (ko) |
AU (1) | AU709645B2 (ko) |
CA (1) | CA2184493C (ko) |
CZ (1) | CZ294650B6 (ko) |
DE (2) | DE69536128D1 (ko) |
DK (3) | DK0754059T4 (ko) |
ES (3) | ES2376850T3 (ko) |
FI (1) | FI121916B (ko) |
HK (1) | HK1013960A1 (ko) |
HU (1) | HU221988B1 (ko) |
MX (1) | MX9604145A (ko) |
NO (1) | NO322441B1 (ko) |
NZ (3) | NZ548433A (ko) |
PT (2) | PT1468695E (ko) |
RU (1) | RU2162712C2 (ko) |
SI (1) | SI0754059T2 (ko) |
SK (1) | SK284586B6 (ko) |
UA (1) | UA44729C2 (ko) |
WO (1) | WO1995025543A1 (ko) |
ZA (1) | ZA952214B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190134204A (ko) * | 2018-05-25 | 2019-12-04 | 고려대학교 산학협력단 | 조직 재생을 위한 Substance P 펩타이드가 고정된 피브린 젤 및 이의 제조방법 |
Families Citing this family (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4310643A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US6949511B1 (en) | 1994-04-26 | 2005-09-27 | The Children's Medical Center Corporation | Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5945403A (en) | 1997-05-30 | 1999-08-31 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US6660842B1 (en) | 1994-04-28 | 2003-12-09 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
DE69531187T2 (de) * | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
US6440729B1 (en) * | 1995-06-30 | 2002-08-27 | University Of Kansas Medical Center | Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen |
US6358735B1 (en) | 1995-06-30 | 2002-03-19 | University Of Kansas Medical Center | Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen |
KR100516322B1 (ko) * | 1995-08-14 | 2005-12-26 | 더 스크립스 리서치 인스티튜트 | αVβ5매개혈관형성의억제를위해유용한조성물 |
US6028223A (en) | 1995-08-30 | 2000-02-22 | G. D. Searle & Co. | Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid compounds and derivatives thereof |
US6100423A (en) * | 1995-08-30 | 2000-08-08 | G. D. Searle & Co. | Amino benzenepropanoic acid compounds and derivatives thereof |
US5854205A (en) * | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
ATE248912T1 (de) | 1995-10-23 | 2003-09-15 | Childrens Medical Center | Therapeutische antiangiogenische zusammensetzungen und verfahren |
US5854221A (en) * | 1996-12-12 | 1998-12-29 | The Children's Medical Center Corporation | Endothelial cell proliferation inhibitor and method of use |
WO1998007035A1 (en) * | 1996-08-15 | 1998-02-19 | Novartis Ag | Assay for quantifying arthritic conditions |
GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
EP0846702B1 (en) * | 1996-12-09 | 2009-03-11 | MERCK PATENT GmbH | Soluble recombinant alphaV beta3 adhesion receptor |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US5837283A (en) | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US7112338B2 (en) | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
EP1491632A3 (en) * | 1997-03-12 | 2006-01-04 | Smithkline Beecham Corporation | Anti-alphavbeta3 humanized monoclonal antibodies |
US5994388A (en) * | 1997-03-18 | 1999-11-30 | The Children's Medical Center Corporation | Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis |
AU6569198A (en) * | 1997-03-19 | 1998-10-12 | Lucid Technologies, Inc. | Cellular surgery utilizing confocal microscopy |
US6193968B1 (en) * | 1997-04-11 | 2001-02-27 | The Burnham Institute | Methods for using anti-αvβ3 integrin antibody |
CA2284726A1 (en) * | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
US6596276B1 (en) * | 1997-09-30 | 2003-07-22 | Beth Israel Deaconess Medical Center | Method for inhibiting tumor angiogenesis in a living subject |
US6372719B1 (en) * | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
US6172256B1 (en) * | 1998-03-04 | 2001-01-09 | G.D. Searle & Co. | Chiral-β-amino acid compounds and derivatives thereof |
US6524553B2 (en) * | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
ATE295369T1 (de) | 1998-03-31 | 2005-05-15 | Bristol Myers Squibb Pharma Co | Pharmazeutika zur bildgebung der angiogenischen krankheiten |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
US6962974B1 (en) | 1998-06-17 | 2005-11-08 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
US7387779B2 (en) | 1998-06-17 | 2008-06-17 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
US6759047B1 (en) * | 1998-06-17 | 2004-07-06 | Beth Israel Deaconess Hospital Corp. | Anti-angiogenic proteins and methods of use thereof |
WO2000002584A2 (en) | 1998-07-13 | 2000-01-20 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
RU2167425C2 (ru) * | 1998-07-17 | 2001-05-20 | Малышев Игорь Юрьевич | Способ определения белков |
US6164281A (en) * | 1998-07-20 | 2000-12-26 | Zhao; Iris Ginron | Method of making and/or treating diseases characterized by neovascularization |
WO2000009143A1 (en) * | 1998-08-13 | 2000-02-24 | G.D. Searle & Co. | Multivalent avb3 and metastasis-associated receptor ligands |
US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
US6703050B1 (en) * | 1998-09-04 | 2004-03-09 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
US6537554B1 (en) | 1998-09-10 | 2003-03-25 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
US7176289B1 (en) * | 1998-09-11 | 2007-02-13 | Vanderbilt University | Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
US6248327B1 (en) | 1998-09-11 | 2001-06-19 | Vanderbilt University | Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
US6235877B1 (en) * | 1999-08-04 | 2001-05-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
US20030202977A1 (en) * | 1998-11-16 | 2003-10-30 | New York University | Treatment of osteoarthritis |
AU766077C (en) * | 1998-11-20 | 2004-10-07 | Genentech Inc. | Uses for Eph receptor antagonists and agonists to treat vascular disorders |
US6339062B1 (en) * | 1998-11-23 | 2002-01-15 | Inkine Pharmaceutical Company, Inc. | Retroinverso polypeptides that mimic or inhibit thrombospondin activity |
US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
US6569402B1 (en) * | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
NZ511677A (en) | 1998-12-18 | 2003-10-31 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
TR200101757T2 (tr) | 1998-12-18 | 2001-12-21 | Dupont Pharmaceuticais Company | Vitronektin reseptör antagonisti farmasötikler |
US6511649B1 (en) * | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
KR20010109275A (ko) * | 1998-12-23 | 2001-12-08 | 로저 에이. 윌리암스 | 종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법 |
US20050281821A1 (en) * | 1999-01-06 | 2005-12-22 | Flavia Pernasetti | Method and composition for angiogenesis inhibition |
US6521593B1 (en) * | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
AU776790B2 (en) * | 1999-02-12 | 2004-09-23 | Lexigen Pharmaceuticals Corporation | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
AU4187200A (en) * | 1999-04-01 | 2000-10-23 | Biostratum, Inc. | The use of domains of type iv collagen t inhibit angiogenesis an tumour growth |
WO2000067771A1 (en) * | 1999-05-06 | 2000-11-16 | The Burnham Institute | Antiangiogenic endostatin peptides, endostatin variants and methods of use |
US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
US6531580B1 (en) * | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
US6685914B1 (en) * | 1999-09-13 | 2004-02-03 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
US20080038274A1 (en) * | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
CN1399554A (zh) * | 1999-09-23 | 2003-02-26 | 斯克里普斯研究学院 | 抑制粘连形成的方法和组合物 |
ATE363290T1 (de) * | 1999-10-04 | 2007-06-15 | Novartis Vaccines & Diagnostic | Cd40 antagonist zur behandlung von psoriasis |
PL356815A1 (en) | 1999-12-22 | 2004-07-12 | The Scripps Research Institute | Angiogenesis and vascular permeability modulators and inhibitors |
US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
KR100767000B1 (ko) | 2000-02-03 | 2007-10-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 인테그린 발현 저해제 |
US7361643B2 (en) | 2000-02-09 | 2008-04-22 | University Of Puerto Rico | Methods for inhibiting angiogenesis |
WO2001058931A1 (en) * | 2000-02-11 | 2001-08-16 | Duke University | Method of treating disorders of the eye |
US6573096B1 (en) * | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
US6835806B2 (en) | 2000-04-03 | 2004-12-28 | Phoenix Pharmaceuticals, Inc. | Cell growth regulation system |
PT1272507E (pt) | 2000-04-12 | 2005-11-30 | Amersham Health As | Derivados de peptidos para ligacao a integrina |
US10293056B1 (en) * | 2000-05-24 | 2019-05-21 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
US7288390B2 (en) * | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
US20030104573A1 (en) * | 2000-09-11 | 2003-06-05 | Shimkets Richard A. | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
NO20004795D0 (no) | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
AU1182402A (en) * | 2000-10-02 | 2002-04-15 | Scripps Research Inst | Methods and compositions for enhancing angiogenesis |
US6632835B2 (en) | 2001-02-22 | 2003-10-14 | Nanodesign Inc. | Dibenzo[c]chromen-6-one derivatives as anti-cancer agents |
DE10109136A1 (de) * | 2001-02-26 | 2002-09-12 | Cytotools Gmbh | Mittel, die die Apoptose bei an der Wundheilung beteiligten Zellen inhibieren |
EP1372720A4 (en) * | 2001-03-02 | 2006-07-26 | Medimmune Inc | PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3 |
PL363311A1 (en) | 2001-04-24 | 2004-11-15 | Merck Patent Gmbh | Combination therapy using anti-angiogenic agents and tnfalpha |
SE0101854L (sv) * | 2001-05-28 | 2002-11-29 | Bioneris Ab | Användning av en förening med en negativt laddad region av grupper för behandling av restenos. |
US7829087B2 (en) * | 2001-07-09 | 2010-11-09 | Elan Pharmaceuticals, Inc. | Methods of treating cognitive impairment |
CA2453403C (en) * | 2001-07-09 | 2013-10-08 | Elan Pharmaceuticals, Inc. | Methods of inhibiting amyloid toxicity |
MXPA04000173A (es) | 2001-07-10 | 2004-03-18 | Amersham Health As | Compuestos basados en peptidos. |
WO2003012122A2 (en) * | 2001-07-27 | 2003-02-13 | University Of Kansas Medical Center | Crystallized structure of type iv collagen nc1 domain hexamer |
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
EP1434584A2 (en) * | 2001-09-05 | 2004-07-07 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
CN100560131C (zh) | 2001-10-22 | 2009-11-18 | 斯克里普斯研究学院 | 抗体靶向化合物 |
PL371281A1 (en) * | 2002-02-14 | 2005-06-13 | Merck Patent Gmbh | Methods and compositions for the treatment of eye diseases |
AU2002306251A1 (en) * | 2002-02-15 | 2003-09-04 | Richard Brunner | 7s immunoglobulin for treatment of choroidal neovascularisation_ |
CA2478317A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
EP1487492A4 (en) * | 2002-03-04 | 2008-10-01 | Medimmune Inc | PREVENTION OR TREATMENT OF CANCER USING INTEGRIN ALPHAVBETA3 ANTAGONISTS COMBINED WITH OTHER AGENTS |
CA2481747A1 (en) * | 2002-04-12 | 2003-10-23 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
NZ596825A (en) | 2002-07-15 | 2013-06-28 | Univ Texas | Duramycin peptides and their use in imaging |
GB0217018D0 (en) * | 2002-07-23 | 2002-08-28 | Bioacta Ltd | Peptide 1 |
MXPA05000875A (es) * | 2002-07-23 | 2005-09-30 | Univ Michigan | Tetratiomolibdato de tetrapropilamonio y compuestos relacionados para terapias anti-angiogenicas. |
US7411048B2 (en) | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
AU2003295644A1 (en) | 2002-11-19 | 2004-07-22 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
US8017737B2 (en) * | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
US20040176272A1 (en) * | 2003-01-30 | 2004-09-09 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
US20040208869A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Uses of anti-integrin alphanubeta3 antibody formulations |
KR20050099536A (ko) | 2003-02-06 | 2005-10-13 | 트리펩 아베 | 글리코실화된 특이성 교환체 |
US7335359B2 (en) * | 2003-02-06 | 2008-02-26 | Tripep Ab | Glycosylated specificity exchangers |
EP1613273B1 (en) * | 2003-04-11 | 2012-06-13 | MedImmune, LLC | Recombinant il-9 antibodies and uses thereof |
WO2004092379A2 (en) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of angiogenic disorders |
CA2525969A1 (en) * | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
US7605235B2 (en) | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
CA2527621A1 (en) * | 2003-05-30 | 2004-12-23 | Centocor, Inc. | Method of inhibiting tumor growth with anti-tissue factor antibodies |
WO2004113361A2 (en) * | 2003-06-20 | 2004-12-29 | The Regents Of The University Of California | Novel prokineticin receptor isoforms and methods of use |
JP2007512347A (ja) * | 2003-11-26 | 2007-05-17 | デューク・ユニバーシティー | 緑内障を予防するかまたは治療する方法 |
CN102258503B (zh) | 2004-01-22 | 2019-08-16 | 迈阿密大学 | 局部辅酶q10制剂及其使用方法 |
US7271245B2 (en) * | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
AU2005215017A1 (en) * | 2004-02-17 | 2005-09-01 | Cancervax Corporation | Method and composition for angiogenesis inhibition |
US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
ES2343424T3 (es) * | 2004-05-07 | 2010-07-30 | The University Of North Carolina At Chapel Hill | Procedimiento para potenciar o inhibir el factor de crecimiento 1 similar a la insulina. |
US8187595B2 (en) | 2004-05-07 | 2012-05-29 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I |
AU2005245896A1 (en) * | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
ES2382661T3 (es) | 2004-06-04 | 2012-06-12 | The Scripps Research Institute | Composiciones y procedimientos para el tratamiento de enfermedades neovasculares |
WO2006012415A2 (en) * | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Rage protein derivatives |
WO2006017619A2 (en) * | 2004-08-06 | 2006-02-16 | The Regents Of The University Of California | Receptor-binding cyclic peptides and methods of use |
US20060040325A1 (en) * | 2004-08-16 | 2006-02-23 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity |
EP1809326A4 (en) | 2004-10-27 | 2009-11-04 | Medimmune Inc | MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN |
KR100679100B1 (ko) * | 2004-10-29 | 2007-02-06 | 엘지.필립스 엘시디 주식회사 | 수평 전계 인가형 액정 표시 패널 및 그 제조방법 |
EP1831254B1 (en) * | 2004-12-23 | 2012-06-06 | Molmed SpA | Conjugation product |
WO2006111925A2 (en) * | 2005-04-18 | 2006-10-26 | Sloan-Kettering Institute For Cancer Research | Inhibition of tumorigenesis by inhibition of a6b4 integrin |
US20090170769A1 (en) * | 2005-05-13 | 2009-07-02 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
US20060286148A1 (en) * | 2005-05-18 | 2006-12-21 | Ppd, Inc. | Method of forming implants |
EP2364998A1 (en) | 2005-06-16 | 2011-09-14 | The Feinstein Institute for Medical Research | Antibodies against HMGB1 and fragments thereof |
WO2007002543A2 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
EP1928497A2 (en) * | 2005-08-24 | 2008-06-11 | Cell-Matrix, Inc. | Combination therapies for inhibiting integrin-extracellular matrix interactions |
JP2009523813A (ja) | 2006-01-18 | 2009-06-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法 |
EP2243488B1 (en) | 2006-01-19 | 2013-08-14 | Eyegene Inc. | Pharmaceutical composition for treating vascular-related diseases comprising peptide |
US20100055093A1 (en) * | 2006-06-12 | 2010-03-04 | Receptor Biologix Inc. | Pan-cell surface receptor-specific therapeutics |
WO2008008373A2 (en) | 2006-07-11 | 2008-01-17 | Arubor Corp | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
CA3177366A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
EA017864B1 (ru) | 2007-01-18 | 2013-03-29 | Мерк Патент Гмбх | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака |
DK2025685T3 (da) * | 2007-08-15 | 2013-09-02 | Canadian Blood Services | Monoklonale antistoffer mod BETA3-integriner. |
MX2010003757A (es) * | 2007-10-16 | 2010-04-27 | Symphogen As | Composiciones que comprenden multimeros optimizados de her1 y her3 y sus metodos de uso. |
EP2219672B1 (en) | 2007-11-09 | 2016-02-17 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
WO2009137807A2 (en) | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
AU2009274512A1 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of Colorado | Clip inhibitors and methods of modulating immune function |
WO2010051531A1 (en) | 2008-10-31 | 2010-05-06 | University Of Louisville Reserch Foundation, Inc. | Olfactory epithelial-derived stem cells and methods of use therefor |
US20110256055A1 (en) | 2008-12-23 | 2011-10-20 | Ge Healthcare Limited | Application of 99mtc peptide-based compound as a bone marrow imaging agent |
US8518927B2 (en) | 2009-02-10 | 2013-08-27 | The Scripps Research Institute | Chemically programmed vaccination |
SG176103A1 (en) | 2009-05-25 | 2011-12-29 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
FR2949782B1 (fr) * | 2009-09-04 | 2015-10-16 | Isp Investments Inc | Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant. |
US8778888B2 (en) * | 2009-11-06 | 2014-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use |
CA2805338A1 (en) | 2010-07-16 | 2012-01-19 | Merck Patent Gmbh | Peptide for use in the treatment of breast cancer and/or bone metastases |
PT2672994T (pt) | 2011-02-11 | 2018-10-22 | Merck Patent Gmbh | Anticorpo anti-integrina alfa-v para o tratamento do cancro da próstata |
US8722044B2 (en) | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
RU2531502C2 (ru) * | 2011-08-09 | 2014-10-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ повышения ангиогенной активности стромальных клеток жировой ткани |
RU2481115C1 (ru) * | 2011-10-13 | 2013-05-10 | Общество с ограниченной ответственностью Научно-Производственное Объединение "Тюменькриобанк" | Средство для заживления ран "целльгель", способ его получения и способ лечения ран различной этиологии полученным средством |
US9775803B2 (en) | 2011-10-19 | 2017-10-03 | Samsung Electronics Co., Ltd. | Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof |
US20140350087A9 (en) | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
KR20150041619A (ko) * | 2012-06-07 | 2015-04-16 | 디씨비-유에스에이 엘엘씨 | 변형된 피브로넥틴 단편 또는 이의 변이체 및 용도 |
EP2890716A4 (en) | 2012-08-31 | 2016-06-08 | Univ North Carolina | MONOCLONAL ANTIBODIES INCREASING OR INHIBITING INSULIN-1 GROWTH FACTOR (IGF-1) |
US9587001B2 (en) | 2012-10-19 | 2017-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
WO2014087429A1 (en) | 2012-12-07 | 2014-06-12 | Council Of Scientific & Industrial Research | Histidinylated cationic amphiphiles, process for preparation thereof and their liposomal formulation |
CN118028463A (zh) * | 2013-03-14 | 2024-05-14 | 儿童医学中心公司 | Cd36鉴定癌症对象以用于治疗的用途 |
US20190144547A1 (en) | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
US10786471B2 (en) | 2017-02-06 | 2020-09-29 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
WO2018183894A1 (en) | 2017-03-31 | 2018-10-04 | The Regents Of The University Of California | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers |
US20220133913A1 (en) * | 2019-07-24 | 2022-05-05 | Korea Basic Science Institute | SINGLE DOMAIN ANTIBODY TARGETING aVB3 INTEGRIN |
EP4007579A4 (en) * | 2019-08-02 | 2023-08-09 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR TARGETING AND DESTRUCTING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSC) AND TREATING DRUG-RESISTANT AND METASTATIC CANCERS |
WO2022047243A1 (en) | 2020-08-27 | 2022-03-03 | Enosi Life Sciences Corp. | Methods and compositions to treat autoimmune diseases and cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5092885A (en) * | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
WO1989005155A1 (en) * | 1987-11-19 | 1989-06-15 | Scripps Clinic And Research Foundation | Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells |
JPH01169343A (ja) | 1987-12-25 | 1989-07-04 | Nippon Sheet Glass Co Ltd | ガラス板の切口欠点検出装置 |
GR1000597B (el) * | 1988-01-19 | 1992-08-26 | Judah Moses Folkman | Παραγοντας αναστολης αναπτυξης και χρηση του. |
US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US5575815A (en) | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
IE901736L (en) * | 1989-05-17 | 1990-11-17 | Fuller H B Licensing Financ | Polypeptide-antibody conjugate for inhibiting cell adhesion |
US5770564A (en) | 1989-06-16 | 1998-06-23 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
US5112946A (en) * | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5262520A (en) * | 1989-12-01 | 1993-11-16 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
US5192744A (en) * | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
EP0470569B1 (en) * | 1990-08-08 | 1995-11-22 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis inhibiting substance |
CA2048078A1 (en) * | 1990-11-15 | 1992-05-16 | Wolfgang A. Wrasidlo | Chemical modification of antibodies for creation of immunoconjugates |
WO1992022653A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
ATE175241T1 (de) * | 1992-04-03 | 1999-01-15 | Genentech Inc | Antikörper gegen alpha v beta 3 integrin |
SK57693A3 (en) * | 1992-06-18 | 1994-07-06 | Merck Patent Gmbh | Linear peptides and pharmaceutical agents on their base |
UA43823C2 (uk) | 1992-07-06 | 2002-01-15 | Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН |
ATE250138T1 (de) | 1992-10-29 | 2003-10-15 | Univ Australian | Angiogenese-inhibierende antikörper |
US6955900B1 (en) * | 1993-02-02 | 2005-10-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof |
DE4310643A1 (de) | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
NZ502819A (en) † | 1993-11-05 | 2002-09-27 | Centocor Inc | Inhibiting stenosis and/or restenosis using for platelets and a human constant region |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5770565A (en) | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
DE19538741A1 (de) | 1995-10-18 | 1997-04-24 | Merck Patent Gmbh | Cyclopeptidderivate |
-
1994
- 1994-03-18 US US08/210,715 patent/US5753230A/en not_active Expired - Lifetime
- 1994-12-30 US US08/366,665 patent/US5766591A/en not_active Expired - Lifetime
-
1995
- 1995-03-09 KR KR1019960705163A patent/KR100327081B1/ko not_active IP Right Cessation
- 1995-03-09 DK DK95913644.1T patent/DK0754059T4/da active
- 1995-03-09 AU AU19952/95A patent/AU709645B2/en not_active Expired
- 1995-03-09 MX MX9604145A patent/MX9604145A/es active IP Right Grant
- 1995-03-09 EP EP03077708A patent/EP1410807B1/en not_active Expired - Lifetime
- 1995-03-09 ES ES03078802T patent/ES2376850T3/es not_active Expired - Lifetime
- 1995-03-09 DE DE69536128T patent/DE69536128D1/de not_active Expired - Lifetime
- 1995-03-09 DE DE69532279T patent/DE69532279T3/de not_active Expired - Lifetime
- 1995-03-09 SK SK1190-96A patent/SK284586B6/sk not_active IP Right Cessation
- 1995-03-09 WO PCT/US1995/003035 patent/WO1995025543A1/en active IP Right Grant
- 1995-03-09 RU RU96120204/14A patent/RU2162712C2/ru not_active IP Right Cessation
- 1995-03-09 NZ NZ548433A patent/NZ548433A/en not_active IP Right Cessation
- 1995-03-09 ES ES03077708T patent/ES2355074T3/es not_active Expired - Lifetime
- 1995-03-09 CN CNB951931334A patent/CN1161152C/zh not_active Expired - Lifetime
- 1995-03-09 AT AT03078802T patent/ATE534403T1/de active
- 1995-03-09 SI SI9530699T patent/SI0754059T2/sl unknown
- 1995-03-09 HU HU9602541A patent/HU221988B1/hu not_active IP Right Cessation
- 1995-03-09 CZ CZ19962711A patent/CZ294650B6/cs not_active IP Right Cessation
- 1995-03-09 UA UA96093689A patent/UA44729C2/uk unknown
- 1995-03-09 PT PT03078802T patent/PT1468695E/pt unknown
- 1995-03-09 NZ NZ511293A patent/NZ511293A/en not_active IP Right Cessation
- 1995-03-09 DK DK03078802.0T patent/DK1468695T3/da active
- 1995-03-09 DK DK03077708.0T patent/DK1410807T3/da active
- 1995-03-09 JP JP52467595A patent/JP4268222B2/ja not_active Expired - Lifetime
- 1995-03-09 ES ES95913644T patent/ES2211901T5/es not_active Expired - Lifetime
- 1995-03-09 EP EP03078802A patent/EP1468695B1/en not_active Expired - Lifetime
- 1995-03-09 NZ NZ283022A patent/NZ283022A/en not_active IP Right Cessation
- 1995-03-09 AT AT03077708T patent/ATE490784T1/de active
- 1995-03-09 AT AT95913644T patent/ATE255907T1/de active
- 1995-03-09 EP EP95913644A patent/EP0754059B2/en not_active Expired - Lifetime
- 1995-03-09 CA CA2184493A patent/CA2184493C/en not_active Expired - Fee Related
- 1995-03-09 PT PT95913644T patent/PT754059E/pt unknown
- 1995-03-17 ZA ZA952214A patent/ZA952214B/xx unknown
-
1996
- 1996-09-17 NO NO19963894A patent/NO322441B1/no not_active IP Right Cessation
- 1996-09-18 FI FI963692A patent/FI121916B/fi not_active IP Right Cessation
-
1998
- 1998-05-19 US US09/081,522 patent/US6887473B1/en not_active Expired - Fee Related
- 1998-12-24 HK HK98115348A patent/HK1013960A1/ not_active IP Right Cessation
-
2004
- 2004-07-15 US US10/892,745 patent/US7482007B2/en not_active Expired - Fee Related
- 2004-07-15 US US10/892,653 patent/US7329406B2/en not_active Expired - Fee Related
- 2004-07-15 US US10/892,789 patent/US7354586B2/en not_active Expired - Fee Related
-
2006
- 2006-05-22 JP JP2006142020A patent/JP4758281B2/ja not_active Expired - Lifetime
-
2007
- 2007-10-30 US US11/980,211 patent/US7595051B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190134204A (ko) * | 2018-05-25 | 2019-12-04 | 고려대학교 산학협력단 | 조직 재생을 위한 Substance P 펩타이드가 고정된 피브린 젤 및 이의 제조방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970701564A (ko) | 맥관형성 억제에 유용한 방법 및 조성물(Methods and compositions useful for inhibition of angiogenesis) | |
RU96120204A (ru) | Способы и композиции, пригодные для ингибирования ангиогенеза | |
Wallach et al. | Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. | |
Weber et al. | Inhibitors of protein tyrosine kinase suppress TNF-stimulated induction of endothelial cell adhesion molecules. | |
RU98123834A (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА | |
ATE191143T1 (de) | Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck | |
DE69425431T2 (de) | 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren | |
KR950704311A (ko) | 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist) | |
EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
JP2017529382A5 (ko) | ||
KR970702251A (ko) | 허혈성 질환에 기인하는 증상의 개선 또는 치료약 및 이에 유용한 화합물(Ameliorant or0 remedy for symptoms caused by ischemic diseases and compounds useful therefor) | |
DE60044365D1 (de) | Loid-ablagerung | |
NZ235877A (en) | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence | |
ATE170845T1 (de) | Plättchenaggregationsinhibitoren | |
ES2180564T3 (es) | 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina. | |
Bruck et al. | Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice. | |
CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
DK0716611T3 (da) | Fremgangsmåde til at reducere myocardielæsion under akut myocardieinfarkt | |
DK0659193T3 (da) | Blodpladeaggregationsinhibitorer | |
DE69629195D1 (de) | Inhibitor von gehirnödemen | |
RU94045271A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера | |
TW470646B (en) | Pharmaceutical composition for use in the treatment of conditions requiring inhibition of vascular smooth muscle cell migration comprising R(+) isomer of amlodipine | |
US2971887A (en) | Inhibition of isoniazid acetylation | |
Hawkes | N-BENZYL-β-CHLOROPROPIONAMIDE (HIBICON®): A New Approach to Anticonvulsant Therapy | |
MX9304075A (es) | Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120206 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20130201 Year of fee payment: 12 |
|
LAPS | Lapse due to unpaid annual fee |